Robert Dickey
Director of Finance/CFO chez AIM IMMUNOTECH INC.
Fortune : - $ au 31/03/2024
Profil
Robert Dickey currently holds three positions as an Independent Director at AngioGenex, Inc., Chief Financial Officer & Director at SFA Therapeutics, Inc., and Chief Financial Officer at AIM ImmunoTech, Inc. Previously, he served as Chief Executive Officer & Chief Operating Officer at Protarga, Inc., Managing Director at Lehman Brothers, Inc., Director at EMI Holding, Inc. and Sanuthera, Inc., Managing Director at Legg Mason Wood Walker, Inc., Managing Director at Danforth Advisors LLC, Independent Director at Emmaus Life Sciences, Inc., Principal at Neuromedical Systems, Inc., Senior Vice President at AIM ImmunoTech, Inc., Chief Financial Officer & Senior Vice President at StemCyte, Inc., Chief Financial Officer at Tyme Technologies, Inc., Chief Financial Officer at Locus Pharmaceuticals, Inc., Chief Financial Officer at Caladrius Biosciences, Inc., Chief Financial Officer at Motif Bio Plc, Chief Financial Officer at Tyme, Inc., and Chief Financial Officer at BeyondSpring Pharmaceuticals, Inc. He also served as Chief Financial Officer at NLS Pharmaceutics Ltd.
and Enveric Biosciences, Inc. Additionally, he holds an undergraduate degree from Princeton University and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AIM IMMUNOTECH INC.
-.--% | 02/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Robert Dickey
| Sociétés | Poste | Début |
|---|---|---|
| ANGIOGENEX, INC. | Director/Board Member | 30/06/2020 |
| AIM IMMUNOTECH INC. | Director of Finance/CFO | 04/04/2022 |
SFA Therapeutics, Inc.
 SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Director of Finance/CFO | 30/12/2021 |
Anciens postes connus de Robert Dickey
| Sociétés | Poste | Fin |
|---|---|---|
| INVITAE CORPORATION | Director of Finance/CFO | 02/10/2023 |
| ENVERIC BIOSCIENCES, INC. | Director of Finance/CFO | 13/03/2023 |
| EMMAUS LIFE SCIENCES, INC. | Director/Board Member | 04/08/2022 |
| NLS PHARMACEUTICS LTD. | Director of Finance/CFO | 04/04/2021 |
Danforth Advisors LLC
 Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Corporate Officer/Principal | 01/03/2020 |
Formation de Robert Dickey
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AIM IMMUNOTECH INC. | Health Technology |
| INVITAE CORPORATION | Health Services |
| NLS PHARMACEUTICS LTD. | Health Technology |
| EMMAUS LIFE SCIENCES, INC. | Health Technology |
| ENVERIC BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 16 |
|---|---|
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
| Neuromedical Systems, Inc. | Health Technology |
| Protarga, Inc. | |
StemCyte, Inc.
 StemCyte, Inc. BiotechnologyHealth Technology StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA. | Health Technology |
EMI Holding, Inc.
 EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Health Technology |
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
| Sanuthera, Inc. | |
| Legg Mason Wood Walker, Inc. | Finance |
Locus Pharmaceuticals, Inc.
 Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation. | Health Technology |
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
AngioGenex, Inc.
 AngioGenex, Inc. Pharmaceuticals: MajorHealth Technology AngioGenex, Inc. operates as a biopharmaceutical company, which engages in developing and commercializing novel platform of anti-proliferative drugs for the treatment of cancer and macular degeneration. The company was founded by Michael M. Strage and Robert Benezra in March 1999 and is headquartered in New York, NY. | Health Technology |
Danforth Advisors LLC
Danforth Advisors LLC Investment ManagersFinance Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Finance |
Tyme, Inc.
 Tyme, Inc. BiotechnologyHealth Technology Part of Syros Pharmaceuticals, Inc., Tyme, Inc. is a private company that provides research and development services focused on developing drug candidates for the treatment of cancer. The company is based in Wilmington, DE. Steve Hoffman has been the CEO of the company since 2013. Tyme was acquired by Tyme Technologies, Inc., part of Syros Pharmaceuticals, Inc. from September 19, 2022 on March 05, 2015. | Health Technology |
BeyondSpring Pharmaceuticals, Inc.
 BeyondSpring Pharmaceuticals, Inc. BiotechnologyHealth Technology Part of BeyondSpring, Inc., BeyondSpring Pharmaceuticals, Inc. is a clinical-stage bio-pharmaceutical company that develops innovative immuno-oncology cancer therapies. The private company is based in New York, NY. The company has a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using a ubiquitination platform. The CEO of the company is Lan Huang. | Health Technology |
SFA Therapeutics, Inc.
SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Technology Services |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
